DE10192353T1 - Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung - Google Patents

Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung

Info

Publication number
DE10192353T1
DE10192353T1 DE10192353T DE10192353T DE10192353T1 DE 10192353 T1 DE10192353 T1 DE 10192353T1 DE 10192353 T DE10192353 T DE 10192353T DE 10192353 T DE10192353 T DE 10192353T DE 10192353 T1 DE10192353 T1 DE 10192353T1
Authority
DE
Germany
Prior art keywords
specificity
antibody molecule
necrosis factor
tumor necrosis
human tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10192353T
Other languages
German (de)
English (en)
Inventor
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Andrew George Popplewell
Andrew Paul Chapman
David John King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA Belgium
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10192353(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of DE10192353T1 publication Critical patent/DE10192353T1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
DE10192353T 2000-06-06 2001-06-05 Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung Withdrawn DE10192353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (1)

Publication Number Publication Date
DE10192353T1 true DE10192353T1 (de) 2003-05-22

Family

ID=9893121

Family Applications (3)

Application Number Title Priority Date Filing Date
DE122010000027C Pending DE122010000027I1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
DE60140738T Expired - Lifetime DE60140738D1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
DE10192353T Withdrawn DE10192353T1 (de) 2000-06-06 2001-06-05 Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE122010000027C Pending DE122010000027I1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
DE60140738T Expired - Lifetime DE60140738D1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung

Country Status (42)

Country Link
US (4) US7012135B2 (OSRAM)
EP (4) EP2308975B1 (OSRAM)
JP (3) JP4064812B2 (OSRAM)
KR (1) KR20020047097A (OSRAM)
CN (1) CN1289671C (OSRAM)
AP (1) AP2092A (OSRAM)
AR (1) AR033978A1 (OSRAM)
AT (1) ATE451460T1 (OSRAM)
AU (1) AU783756B2 (OSRAM)
BE (1) BE2010C019I2 (OSRAM)
BG (1) BG66072B1 (OSRAM)
BR (2) BR0106682A (OSRAM)
CA (2) CA2707766C (OSRAM)
CY (6) CY1109889T1 (OSRAM)
CZ (1) CZ300737B6 (OSRAM)
DE (3) DE122010000027I1 (OSRAM)
DK (4) DK3059314T3 (OSRAM)
EC (1) ECSP024210A (OSRAM)
ES (5) ES2403217T3 (OSRAM)
FR (1) FR10C0015I2 (OSRAM)
GB (2) GB0013810D0 (OSRAM)
HU (4) HU230561B1 (OSRAM)
IL (3) IL147992A0 (OSRAM)
IS (2) IS2808B (OSRAM)
LT (1) LT2308975T (OSRAM)
LU (1) LU91674I2 (OSRAM)
MX (1) MXPA01013440A (OSRAM)
MY (1) MY136603A (OSRAM)
NL (1) NL300982I9 (OSRAM)
NO (4) NO334808B1 (OSRAM)
NZ (1) NZ516596A (OSRAM)
OA (1) OA12282A (OSRAM)
PE (1) PE20020292A1 (OSRAM)
PL (2) PL212738B1 (OSRAM)
PT (4) PT3059314T (OSRAM)
RU (1) RU2303604C2 (OSRAM)
SI (3) SI2230308T1 (OSRAM)
SK (1) SK288343B6 (OSRAM)
TR (1) TR201900227T4 (OSRAM)
TW (2) TWI316088B (OSRAM)
WO (1) WO2001094585A1 (OSRAM)
ZA (1) ZA200200097B (OSRAM)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US20060171940A1 (en) * 2002-03-20 2006-08-03 Celltech R&D Limited Antibody disulfide isomers, use thereof, and methods of analyzing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
PL224001B1 (pl) * 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
WO2003099226A2 (en) * 2002-05-28 2003-12-04 Celltech R & D Limited Antibody peg positional isomers, compositions comprising same, and use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
MY151032A (en) * 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
CA2508375C (en) 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
CA2529819A1 (en) * 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
US20060173167A1 (en) * 2003-08-13 2006-08-03 Gunter Stempfer Process for the purification of recombinant polypeptides
EP1656452B1 (en) * 2003-08-13 2007-02-14 Sandoz AG Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
EP1831257B9 (en) * 2004-12-29 2011-05-04 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US7964707B2 (en) * 2005-06-01 2011-06-21 Micromet Ag Anti-IL2 antibodies
RS52861B (sr) * 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
EP2666472A3 (en) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP5452236B2 (ja) * 2007-03-02 2014-03-26 ファーナム・カンパニーズ・インコーポレーテッド ロウ様物質を用いた徐放性組成物
CA2690858A1 (en) * 2007-06-07 2008-12-18 Surmodics Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
BRPI0907485A2 (pt) * 2008-02-05 2015-08-04 Delenex Therapeutics Ag Polipeptídeos de ligação a antígeno contra degeneração de cartilagem
BRPI0912570B8 (pt) * 2008-05-07 2021-05-25 Argos Therapeutics Inc anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
MX2011000052A (es) 2008-06-25 2011-07-29 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
BRPI0914663A2 (pt) 2008-06-25 2015-10-20 Esbatech Alcon Biomed Res Unit humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
LT3444274T (lt) 2008-06-25 2021-03-25 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys tnf
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
SMT201800549T1 (it) 2009-09-24 2018-11-09 Ucb Biopharma Sprl Ceppo batterico per espressione di proteina ricombinante, avente attivita' di chaperone a conservazione di degp carente di proteasi, e geni tsp e ptr con knockout
CA3031851C (en) 2009-10-23 2020-07-07 Amgen British Columbia Anti-gcc antibody molecules and related compositions and methods
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011109662A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JP6175428B2 (ja) 2011-06-01 2017-08-02 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 細菌のポリシストロン性発現系
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
MX348738B (es) 2011-07-13 2017-06-27 Ucb Pharma Sa Cepa huesped bacteriana que expresa dsbc recombinante.
DK2758513T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
MX357675B (es) 2012-08-13 2018-07-18 Genentech Inc Anticuerpos anti-jagged y métodos de uso.
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
PT3237433T (pt) 2014-12-22 2025-10-21 Ucb Biopharma Sprl Método de fabrico de proteína
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2760997C2 (ru) 2016-01-14 2021-12-02 Интрексон Актобиотикс Н.В. Композиции и способы для лечения диабета 1 типа
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
LT3464318T (lt) 2016-06-02 2021-06-25 Abbvie Inc. Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
PE20201286A1 (es) 2017-12-01 2020-11-24 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados de este
CN113631574B (zh) 2019-01-31 2025-03-04 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240226295A9 (en) 2021-02-15 2024-07-11 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
KR20240099199A (ko) 2021-09-24 2024-06-28 엑스브레인 바이오파마 에이비 재조합 단백질을 발현시키기 위한 dna 구조체 및 숙주 세포
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1994029347A1 (en) * 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0871641A4 (en) 1995-04-20 2001-09-26 Kennedy Inst Of Rheumatology MULTIPLE ADMINISTRATION OF ANTI-TNF ANTIBODIES
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CA2297692A1 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
CN1383450A (zh) 2002-12-04
BR0106682A (pt) 2002-05-14
CY1121173T1 (el) 2020-05-29
TWI316088B (en) 2009-10-21
DK2308975T3 (da) 2016-10-31
OA12282A (en) 2006-05-11
CA2380298C (en) 2010-09-28
PT2308975T (pt) 2016-11-14
DK2230308T3 (da) 2013-05-06
US7402662B2 (en) 2008-07-22
IL195085A0 (en) 2009-08-03
AP2092A (en) 2010-02-28
NO20160694A1 (no) 2002-04-08
KR20020047097A (ko) 2002-06-21
ES2230975A1 (es) 2005-05-01
GB0013810D0 (en) 2000-07-26
AR033978A1 (es) 2004-01-21
PT2230308E (pt) 2013-05-03
ECSP024210A (es) 2002-05-23
WO2001094585A1 (en) 2001-12-13
SK288343B6 (sk) 2016-04-01
PL218516B1 (pl) 2014-12-31
HUP1600016A2 (en) 2002-10-28
JP2007105043A (ja) 2007-04-26
HK1148776A1 (en) 2011-09-16
IL147992A0 (en) 2002-09-12
IS6217A (is) 2002-01-03
SK3152002A3 (en) 2002-07-02
EP3059314B1 (en) 2018-10-24
EP2308975A1 (en) 2011-04-13
JP2009171966A (ja) 2009-08-06
PT1287140E (pt) 2010-03-08
BG106278A (bg) 2002-12-29
IL147992A (en) 2009-06-15
US20060233800A1 (en) 2006-10-19
FR10C0015I1 (OSRAM) 2010-04-16
CA2707766C (en) 2013-05-21
EP3059314A1 (en) 2016-08-24
EP2308975B1 (en) 2016-08-10
CY1114143T1 (el) 2016-07-27
PL399351A1 (pl) 2012-12-17
NO20020554L (no) 2002-04-08
AU783756B2 (en) 2005-12-01
FR10C0015I2 (fr) 2011-12-30
BG66072B1 (bg) 2011-01-31
ES2707714T3 (es) 2019-04-04
JP4064812B2 (ja) 2008-03-19
US20020151682A1 (en) 2002-10-17
ES2337763T3 (es) 2010-04-29
ES2403217T3 (es) 2013-05-16
RU2303604C2 (ru) 2007-07-27
ES2600080T3 (es) 2017-02-07
CY1109889T1 (el) 2012-01-25
JP4476989B2 (ja) 2010-06-09
PE20020292A1 (es) 2002-05-08
HU230561B1 (hu) 2016-12-28
PL212738B1 (pl) 2012-11-30
MY136603A (en) 2008-10-31
HK1051385A1 (en) 2003-08-01
GB2366800A (en) 2002-03-20
NO339282B1 (no) 2016-11-21
TWI353358B (en) 2011-12-01
HU230669B1 (hu) 2017-07-28
NO2014026I1 (no) 2014-10-23
BRPI0106682B8 (pt) 2021-05-25
ZA200200097B (en) 2003-01-06
JP2003535591A (ja) 2003-12-02
SI2308975T1 (sl) 2016-11-30
US7977464B2 (en) 2011-07-12
PL353960A1 (en) 2003-12-15
DE122010000027I1 (de) 2010-08-12
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
LT2308975T (lt) 2016-11-10
PT3059314T (pt) 2019-02-01
NZ516596A (en) 2004-07-30
IS3016B (is) 2019-10-15
EP2230308A1 (en) 2010-09-22
IS2808B (is) 2012-09-15
EP1287140B1 (en) 2009-12-09
ES2230975B2 (es) 2007-04-16
AP2002002690A0 (en) 2002-12-31
CA2380298A1 (en) 2001-12-13
CN1289671C (zh) 2006-12-13
NO334808B1 (no) 2014-06-02
CY2010011I1 (el) 2012-01-25
US7186820B2 (en) 2007-03-06
CY1118220T1 (el) 2017-06-28
BRPI0106682B1 (pt) 2020-10-13
EP1287140A1 (en) 2003-03-05
GB2366800B (en) 2005-01-19
EP2230308B1 (en) 2013-01-23
TR201900227T4 (tr) 2019-02-21
CZ300737B6 (cs) 2009-07-29
NL300982I9 (nl) 2019-05-06
BE2010C019I2 (OSRAM) 2020-08-20
NO20020554D0 (no) 2002-02-04
NL300982I1 (OSRAM) 2019-05-01
CA2707766A1 (en) 2001-12-13
LU91674I9 (OSRAM) 2019-01-03
CY2019018I2 (el) 2020-05-29
DE60140738D1 (de) 2010-01-21
US20080269465A1 (en) 2008-10-30
HUP0202346A3 (en) 2004-11-29
CY2019018I1 (el) 2020-05-29
DK1287140T3 (da) 2010-04-19
SI2230308T1 (sl) 2013-06-28
US7012135B2 (en) 2006-03-14
HUP0202346A2 (en) 2002-10-28
NO2014026I2 (no) 2018-02-14
NO341218B1 (no) 2017-09-11
CZ2002837A3 (cs) 2002-05-15
HUP1600483A2 (OSRAM) 2002-10-28
SI1287140T1 (sl) 2010-04-30
LU91674I2 (fr) 2010-05-31
NO20131316L (no) 2002-04-08
TW200817430A (en) 2008-04-16
AU6051101A (en) 2001-12-17
DK3059314T3 (en) 2019-02-18
MXPA01013440A (es) 2003-09-04
HUS1700013I1 (hu) 2017-08-28
US20030026805A1 (en) 2003-02-06
GB0128386D0 (en) 2002-01-16
HU230553B1 (hu) 2016-11-28
JP5185143B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
DE10192353T1 (de) Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
ATE402191T1 (de) Rekombinante il-18 antikörper und deren verwendung
DE60229509D1 (de) Anti-osteopontin-antikörper und dessen verwendung
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE378356T1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
DE60128938D1 (de) Zeolithe und deren verwendung
DE60124071D1 (de) Porphyrin enthaltende milchsäurebakterien und deren verwendung
DE60124905D1 (de) Basischer feststoffkatalysator und dessen verwendung in basischer katalyse
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DE69900802D1 (de) MnMgCuZn-Ferrit und dessen Verwendung
EP1311282A4 (en) HIGH AFFINIT INT-GRIN POLYPEPTIDES AND USES THEREOF
DE60237322D1 (de) Ganglioside-assozierte rekombinante Antikörper und deren Gebrauch fuer Diagnose und Therapien von Tumoren

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: UCB PHARMA S.A., BRUESSEL/BRUXELLES, BE

8141 Disposal/no request for examination